Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40


TAK228 enhances antitumor activity of eribulin in triple negative breast cancer.

Owusu-Brackett N, Evans KW, Akcakanat A, Yuca E, Tapia C, Rizvi YQ, Dumbrava EI, Janku F, Meric-Bernstam F.

Oncotarget. 2019 Aug 20;10(49):5011-5019. doi: 10.18632/oncotarget.27082. eCollection 2019 Aug 20.


Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.

Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F.

Breast Cancer Res. 2019 Jul 5;21(1):78. doi: 10.1186/s13058-019-1154-8.


MK-2206 window of opportunity study in breast cancer.

Akcakanat A, Meric-Bernstam F.

Ann Transl Med. 2018 Nov;6(Suppl 1):S57. doi: 10.21037/atm.2018.10.32. No abstract available.


A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.

Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F.

Clin Cancer Res. 2017 Nov 1;23(21):6468-6477. doi: 10.1158/1078-0432.CCR-17-0615.


Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer.

Woo SU, Sangai T, Akcakanat A, Chen H, Wei C, Meric-Bernstam F.

Oncogenesis. 2017 Oct 9;6(10):e385. doi: 10.1038/oncsis.2017.86.


Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.

Arango NP, Yuca E, Zhao M, Evans KW, Scott S, Kim C, Gonzalez-Angulo AM, Janku F, Ueno NT, Tripathy D, Akcakanat A, Naing A, Meric-Bernstam F.

Breast Cancer Res. 2017 Aug 15;19(1):93. doi: 10.1186/s13058-017-0878-6.


Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.

McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin A, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F.

PLoS One. 2016 Mar 8;11(3):e0151121. doi: 10.1371/journal.pone.0151121. eCollection 2016. No abstract available.


Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.

McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin A, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F.

PLoS One. 2015 Sep 1;10(9):e0136851. doi: 10.1371/journal.pone.0136851. eCollection 2015. Erratum in: PLoS One. 2016;11(3):e0151121.


Epithelial to mesenchymal transition is associated with rapamycin resistance.

Holder AM, Akcakanat A, Adkins F, Evans K, Chen H, Wei C, Milton DR, Li Y, Do KA, Janku F, Meric-Bernstam F.

Oncotarget. 2015 Aug 14;6(23):19500-13.


SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.

Gonzalez-Angulo AM, Krop I, Akcakanat A, Chen H, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin AA, Doyle LA, Do KA, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F.

J Natl Cancer Inst. 2015 Feb 16;107(3). pii: dju493. doi: 10.1093/jnci/dju493. Print 2015 Mar.


Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.

Hassan B, Akcakanat A, Sangai T, Evans KW, Adkins F, Eterovic AK, Zhao H, Chen K, Chen H, Do KA, Xie SM, Holder AM, Naing A, Mills GB, Meric-Bernstam F.

Oncotarget. 2014 Sep 30;5(18):8544-57.


Influence of biospecimen variables on proteomic biomarkers in breast cancer.

Meric-Bernstam F, Akcakanat A, Chen H, Sahin A, Tarco E, Carkaci S, Adrada BE, Singh G, Do KA, Garces ZM, Mittendorf E, Babiera G, Bedrosian I, Hwang R, Krishnamurthy S, Symmans WF, Gonzalez-Angulo AM, Mills GB.

Clin Cancer Res. 2014 Jul 15;20(14):3870-83. doi: 10.1158/1078-0432.CCR-13-1507. Epub 2014 Jun 3.


PD-L1 expression in triple-negative breast cancer.

Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G.

Cancer Immunol Res. 2014 Apr;2(4):361-70. doi: 10.1158/2326-6066.CIR-13-0127. Epub 2014 Jan 10.


Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.

Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F.

Ann Oncol. 2014 Jun;25(6):1122-7. doi: 10.1093/annonc/mdu124. Epub 2014 Mar 24.


Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.

Blanco E, Sangai T, Wu S, Hsiao A, Ruiz-Esparza GU, Gonzalez-Delgado CA, Cara FE, Granados-Principal S, Evans KW, Akcakanat A, Wang Y, Do KA, Meric-Bernstam F, Ferrari M.

Mol Ther. 2014 Jul;22(7):1310-1319. doi: 10.1038/mt.2014.27. Epub 2014 Feb 26.


Targeting translation initiation in breast cancer.

Akcakanat A, Hong DS, Meric-Bernstam F.

Translation (Austin). 2014 Apr 29;2(1):e28968. doi: 10.4161/trla.28968. eCollection 2014. Review.


Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial.

Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, Chen H, Naing A, Fu S, Wheler J, Moulder S, Helgason T, Li S, Elias I, Desai N, Kurzrock R.

Clin Cancer Res. 2013 Oct 1;19(19):5474-84. doi: 10.1158/1078-0432.CCR-12-3110.


Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Hassan B, Akcakanat A, Holder AM, Meric-Bernstam F.

Surg Oncol Clin N Am. 2013 Oct;22(4):641-64. doi: 10.1016/j.soc.2013.06.008. Epub 2013 Aug 6. Review.


High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients.

Holder AM, Gonzalez-Angulo AM, Chen H, Akcakanat A, Do KA, Fraser Symmans W, Pusztai L, Hortobagyi GN, Mills GB, Meric-Bernstam F.

Breast Cancer Res Treat. 2013 Jan;137(1):319-27. doi: 10.1007/s10549-012-2354-4. Epub 2012 Dec 4.


Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer.

Meric-Bernstam F, Chen H, Akcakanat A, Do KA, Lluch A, Hennessy BT, Hortobagyi GN, Mills GB, Gonzalez-Angulo A.

Breast Cancer Res. 2012 Oct 26;14(5):R138. doi: 10.1186/bcr3343.


Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.

Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, Miller TW, Arteaga CL, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F.

Clin Cancer Res. 2012 Oct 15;18(20):5816-28. doi: 10.1158/1078-0432.CCR-12-1141. Epub 2012 Aug 29.


PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.

Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, Gonzalez-Angulo AM, Rashid A, Crosby K, Dong M, Phan AT, Wolff RA, Gupta S, Mills GB, Yao J.

Clin Cancer Res. 2012 Mar 15;18(6):1777-89. doi: 10.1158/1078-0432.CCR-11-2123.


Targeting PI3K/mTOR signaling in cancer.

Emerling BM, Akcakanat A.

Cancer Res. 2011 Dec 15;71(24):7351-9. doi: 10.1158/0008-5472.CAN-11-1699. Epub 2011 Oct 10.


The effect of leucine restriction on Akt/mTOR signaling in breast cancer cell lines in vitro and in vivo.

Singh G, Akcakanat A, Sharma C, Luyimbazi D, Naff KA, Meric-Bernstam F.

Nutr Cancer. 2011;63(2):264-71. doi: 10.1080/01635581.2011.523504.


Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer.

Luyimbazi D, Akcakanat A, McAuliffe PF, Zhang L, Singh G, Gonzalez-Angulo AM, Chen H, Do KA, Zheng Y, Hung MC, Mills GB, Meric-Bernstam F.

Mol Cancer Ther. 2010 Oct;9(10):2770-84. doi: 10.1158/1535-7163.MCT-09-0980. Epub 2010 Sep 28.


The rapamycin-regulated gene expression signature determines prognosis for breast cancer.

Akcakanat A, Zhang L, Tsavachidis S, Meric-Bernstam F.

Mol Cancer. 2009 Sep 24;8:75. doi: 10.1186/1476-4598-8-75.


RNA-binding specificity of Y-box protein 1.

Dong J, Akcakanat A, Stivers DN, Zhang J, Kim D, Meric-Bernstam F.

RNA Biol. 2009 Jan-Mar;6(1):59-64. Epub 2009 Jan 19.


Regulation and localization of ribosomal protein S6 kinase 1 isoforms.

Kim D, Akcakanat A, Singh G, Sharma C, Meric-Bernstam F.

Growth Factors. 2009 Feb;27(1):12-21. doi: 10.1080/08977190802556986.


eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling.

Soni A, Akcakanat A, Singh G, Luyimbazi D, Zheng Y, Kim D, Gonzalez-Angulo A, Meric-Bernstam F.

Mol Cancer Ther. 2008 Jul;7(7):1782-8. doi: 10.1158/1535-7163.MCT-07-2357.


Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases.

Akcakanat A, Sahin A, Shaye AN, Velasco MA, Meric-Bernstam F.

Cancer. 2008 Jun;112(11):2352-8. doi: 10.1002/cncr.23456.


Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors.

Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F.

Endocr Relat Cancer. 2008 Mar;15(1):257-66. doi: 10.1677/ERC-07-0202.


Rapamycin regulates the phosphorylation of rictor.

Akcakanat A, Singh G, Hung MC, Meric-Bernstam F.

Biochem Biophys Res Commun. 2007 Oct 19;362(2):330-3. Epub 2007 Aug 8.


Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy.

Akcakanat A, Kanda T, Tanabe T, Komukai S, Yajima K, Nakagawa S, Ohashi M, Hatakeyama K.

Int J Cancer. 2006 Jan 1;118(1):123-8.


NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer.

Akcakanat A, Kanda T, Koyama Y, Watanabe M, Kimura E, Yoshida Y, Komukai S, Nakagawa S, Odani S, Fujii H, Hatakeyama K.

Cancer Chemother Pharmacol. 2004 Jul;54(1):95-100. Epub 2004 Apr 30.


Diagnostic criteria of colospasm at barium enema examination.

Unal M, Celik E, Akçali A, Akçakanat A.

Acta Radiol. 2002 Nov;43(6):629-30. No abstract available.


Inflammatory response to open tension-free inguinal hernioplasty versus conventional repair.

Bozkurt MK, Ağalar F, Akçakanat A.

Am J Surg. 2000 Jan;179(1):76. No abstract available.


Correlation between teaching ability and examination scores.

Akcakanat A, Agalar F.

Am J Surg. 1999 Nov;178(5):434-5. No abstract available.


Evaluation of trauma care in a developing country highlighted by a major aircraft accident.

Ağalar F, Cakmakçi M, Er M, Akçakanat A, Sayek I.

Eur J Emerg Med. 1997 Jun;4(2):97-102.


Study of interleukin-10 and experimental acute pancreatitis.

Akçakanat A, Ağalar F, Hayran M, Sayek I.

Surgery. 1997 Jun;121(6):719-20. No abstract available.


Pulmonary function after laparoscopic cholecystectomy in the elderly.

Ağalar F, Akçakanat A, Hayran M, Sayek I.

Br J Surg. 1997 Apr;84(4):579. No abstract available.


Supplemental Content

Loading ...
Support Center